Acornmed
AcornMed Biotechnology Co., Ltd. (金橡医学) is a Beijing-headquartered precision-oncology company founded in 2018, with subsidiaries in Tianjin and Qingdao. It develops and operates next-generation-sequencing (NGS) diagnostics for solid tumors and hematologic malignancies — the AcornUI urine-based series for bladder, ureteral and renal-pelvic cancer rule-out and recurrence monitoring, AcornUPro-SEEK for prostate cancer screening, AcornOne 808 for solid tumors and AcornHema 521 for blood cancers — alongside CAP/ISO 15189 central-laboratory testing, companion-diagnostic co-development and real-world-data services for pharmaceutical partners. AcornMed is a clinical laboratory and IVD developer: it sells testing services to hospitals, physicians and pharma sponsors and publishes no public developer program, API, or machine-readable contract of any kind.
Acornmed is profiled on the APIs.io network. Tagged areas include Company, Health, Healthcare, Life Sciences, and Biotechnology.
Acornmed’s developer surface includes support, engineering blog, and 7 more developer resources.
Kin Score
Pricing Plans 1
Published pricing tiers and plan structures.
Rate Limits 1
Documented rate limits and quota policies.
Acornmed Rate Limits
RATE LIMITSSecurity Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.